JY
ALXN

Jeff Yass’s Alexion Pharmaceuticals ALXN Stock Holding History

Jeff Yass’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-81,039
Closed -$14.9M – 14111
2021
Q2 		$14.9M Buy
81,039
+52,490
+184% +$9.01M ﹤0.01% 2378
2021
Q1 		$4.37M Sell
28,549
-164,427
-85% -$25.4M ﹤0.01% 4180
2020
Q4 		$30.2M Sell
192,976
-282,353
-59% -$36.3M ﹤0.01% 1365
2020
Q3 		$54.4M Buy
475,329
+173,390
+57% +$18.7M 0.01% 825
2020
Q2 		$33.9M Sell
301,939
-575,642
-66% -$61.1M 0.01% 1037
2020
Q1 		$78.8M Buy
877,581
+381,777
+77% +$37.5M 0.03% 477
2019
Q4 		$53.6M Buy
495,804
+66,769
+16% +$7.14M 0.02% 775
2019
Q3 		$42M Buy
429,035
+288,849
+206% +$32.6M 0.01% 840
2019
Q2 		$18.4M Buy
+140,186
New +$18.1M 0.01% 1338
2019
Q1 		– Sell
-65,654
Closed -$8.16M – 10244
2018
Q4 		$6.39M Buy
65,654
+33,383
+103% +$3.95M ﹤0.01% 2029
2018
Q3 		$4.49M Sell
32,271
-153,358
-83% -$19.2M ﹤0.01% 2822
2018
Q2 		$23M Sell
185,629
-135,271
-42% -$15.8M 0.01% 1190
2018
Q1 		$35.8M Buy
320,900
+87,082
+37% +$10.4M 0.01% 826
2017
Q4 		$28M Buy
233,818
+211,611
+953% +$25.8M 0.01% 1019
2017
Q3 		$3.12M Sell
22,207
-372,967
-94% -$50.7M ﹤0.01% 3180
2017
Q2 		$48.1M Buy
395,174
+197,301
+100% +$23M 0.02% 627
2017
Q1 		$24M Sell
197,873
-164,675
-45% -$21.2M 0.01% 954
2016
Q4 		$44.4M Buy
362,548
+147,742
+69% +$18.1M 0.02% 607
2016
Q3 		$26.3M Buy
214,806
+208,042
+3,076% +$26.8M 0.01% 840
2016
Q2 		$790K Sell
6,764
-5,911
-47% -$839K ﹤0.01% 5324
2016
Q1 		$1.76M Sell
12,675
-3,444
-21% -$506K ﹤0.01% 4011
2015
Q4 		$3.07M Sell
16,119
-106,451
-87% -$18.6M ﹤0.01% 3235
2015
Q3 		$19.2M Buy
122,570
+33,726
+38% +$6.15M 0.01% 1237
2015
Q2 		$16.1M Buy
88,844
+47,865
+117% +$8.26M 0.01% 1517
2015
Q1 		$7.1M Sell
40,979
-28,711
-41% -$5.2M ﹤0.01% 2260
2014
Q4 		$12.9M Sell
69,690
-60,047
-46% -$11.1M 0.01% 1748
2014
Q3 		$21.5M Sell
129,737
-43,302
-25% -$7.11M 0.01% 1341
2014
Q2 		$27M Sell
173,039
-34,691
-17% -$5.48M 0.01% 1131
2014
Q1 		$31.6M Buy
207,730
+132,681
+177% +$21.1M 0.01% 903
2013
Q4 		$9.99M Sell
75,049
-30,078
-29% -$3.61M ﹤0.01% 2072
2013
Q3 		$12.2M Sell
105,127
-60,545
-37% -$6.64M 0.01% 1686
2013
Q2 		$15.3M Buy
+165,672
New +$16M 0.01% 1363

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Jeff Yass's ALXN Position: Q3 2021 in Review

Jeff Yass sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 81,039 shares — an estimated $14.9M sold.

Jeff Yass first reported a position in ALXN in Q2 2013 and held it in 32 quarters. The position peaked at $78.8M in Q1 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Jeff Yass reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Jeff Yass sold 81,039 Alexion Pharmaceuticals shares in Q3 2021, an estimated $14.9M.
  • Jeff Yass first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 32 quarters.
  • Jeff Yass's Alexion Pharmaceuticals position peaked at $78.8M in Q1 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Susquehanna International Group's 13F filing for Q3 2021, filed 15 Nov 2021.